PHIO PHARMACEUTICALS CORP. Gain (Loss) on Extinguishment of Debt
PHIO PHARMACEUTICALS CORP. (PHIO) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2023-03-22
- PHIO PHARMACEUTICALS CORP. gain (loss) on extinguishment of debt for the quarter ending 2022-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. gain (loss) on extinguishment of debt for the quarter ending 2022-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- PHIO PHARMACEUTICALS CORP. gain (loss) on extinguishment of debt for fiscal 2021 was $233.00K.
- PHIO PHARMACEUTICALS CORP. gain (loss) on extinguishment of debt for fiscal 2020 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $0.00 10-K · filed 2023-03-22 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $0.00 derived: sum of 3 quarters · filed 2023-03-22 | $233.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $233.00K 10-Q · filed 2022-11-10 | $233.00K derived: sum of 4 quarters · filed 2022-03-22 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $233.00K 10-Q · filed 2022-08-11 | $233.00K derived: sum of 3 quarters · filed 2022-03-22 | $233.00K derived: sum of 4 quarters · filed 2022-03-22 |
| 2021-03-31 | $233.00K 10-Q · filed 2021-05-13 | $233.00K derived: sum of 2 quarters · filed 2022-03-22 | $233.00K derived: sum of 3 quarters · filed 2022-03-22 | $233.00K derived: sum of 4 quarters · filed 2022-03-22 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $0.00 derived: sum of 2 quarters · filed 2022-03-22 | $0.00 derived: sum of 3 quarters · filed 2022-03-22 | $0.00 10-K · filed 2022-03-22 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |